Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry DiseasePRNewsWire • 05/05/23
Protalix BioTherapeutics Reports First Quarter 2023 Financial and Business ResultsPRNewsWire • 05/04/23
Protalix BioTherapeutics to Announce First Quarter 2023 Financial and Business Results on May 4, 2023PRNewsWire • 04/27/23
Protalix BioTherapeutics Announces First Patient Dosed in First in Human Phase I Clinical Trial of PRX-115 for the Treatment of Severe GoutPRNewsWire • 03/21/23
Protalix BioTherapeutics Issues Statement Related to Silicon Valley Bank and Signature BankPRNewsWire • 03/13/23
Protalix BioTherapeutics Reports Fiscal Year 2022 Financial and Business ResultsPRNewsWire • 02/27/23
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry DiseasePRNewsWire • 02/24/23
Protalix BioTherapeutics to Hold Fiscal Year 2022 Financial and Business Results Conference Call on February 27, 2023PRNewsWire • 02/21/23
Protalix BioTherapeutics to Delist its Common Stock from the Tel Aviv Stock ExchangePRNewsWire • 12/21/22
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of a Resubmitted Biologics License Application for Pegunigalsidase Alfa for the Proposed Treatment of Fabry DiseasePRNewsWire • 12/05/22
Protalix BioTherapeutics Reports Third Quarter 2022 Financial and Business ResultsPRNewsWire • 11/14/22
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Resubmission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry DiseasePRNewsWire • 11/14/22
Protalix BioTherapeutics to Report Third Quarter 2022 Financial and Business Results on November 14, 2022PRNewsWire • 11/07/22